Early phase clinical studies of AR‐42, a histone deacetylase inhibitor, for neurofibromatosis type 2‐associated vestibular schwannomas and meningiomas
Abstract
Two pilot studies of AR‐42, a pan‐histone deacetylase inhibitor, in human neurofibromatosis type 2 (NF2), vestibular schwannomas (VS), and meningiomas are presented. Primary endpoints included safety, and intra‐tumoral pharmacokinetics (PK) and pharmacodynamics (PD).
Document Details
- Document Type
- Pub Defense Publication
- Publication Date
- Aug 20, 2021
- Source ID
- 10.1002/lio2.643
Entities
People
- Amir Mortazavi
- Beth A. Miles‐markley
- Brian A. Neff
- Craig C. Hofmeister
- D Bradley Welling
- Edina Shu
- H. Wayne Slone
- Jaishri O Blakeley
- Janet L. Oblinger
- Katharine A. Collier
- Long‐sheng Chang
- Mina S. Makary
- Robert K Jackler
- S. Alireza Mansouri
- Sarah S. Burns
Organizations
- Emory University
- Harvard Medical School
- Johns Hopkins University
- Mayo Clinic
- National Cancer Institute
- Nationwide Children's Hospital
- Ohio State University
- Stanford University
- United States Department of Defense